Bio-Thera Solutions Announces First Patient Dosed in Australia for BAT6021, an ADCC-enhanced Monoclonal Antibody Targeting TIGIT for the Treatment of Solid Tumors
GUANGZHOU, China--(BUSINESS WIRE)--#AUSTRALIA--Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, today announced that dosing…